COPD maintenance therapy with tiotropium/olodaterol vs LABA/ICS: A real-world study

22 Oct 2020
Interview with Professor Jennifer Quint from the Imperial College London, UK, on the role of tiotropium/olodaterol as chronic obstructive pulmonary disease (COPD) maintenance therapy in reducing the risk of escalation to triple therapy or development of adverse outcomes, as shown in a real-world study.

Related MIMS Drugs

Editor's Recommendations